Key Takeaways & Executive Findings
- •• TDM significantly improves the efficacy and safety of anticancer drug therapy by enabling personalized dosing. • Integration of pharmacogenomics and real-time monitoring technologies is set to revolutionize TDM practices. • Standardized protocols and multidisciplinary collaboration are essential for the successful implementation of TDM in clinical settings. • Future research should focus on overcoming barriers such as cost, accessibility, and the need for robust clinical evidence.
Abstract
Therapeutic drug monitoring (TDM) is a crucial tool in the management of anticancer drug therapy, aiming to optimize drug exposure and minimize toxicity. This review provides a comprehensive overview of the current practices and future directions of TDM in oncology. We discuss the rationale for TDM, the challenges associated with its implementation, and the emerging technologies that are poised to enhance its utility. Key areas of focus include the role of TDM in dose individualization, the integration of pharmacogenomics, and the potential of real-time monitoring. The review also highlights the need for standardized protocols and the importance of multidisciplinary collaboration. Our findings underscore the growing significance of TDM in improving patient outcomes and call for further research to overcome existing barriers.
1. Introduction
Therapeutic drug monitoring (TDM) has emerged as a pivotal component in the management of anticancer drug therapy. By measuring drug concentrations in biological fluids, TDM enables clinicians to tailor dosing regimens to individual patient needs, thereby maximizing therapeutic efficacy while minimizing adverse effects. The inherent narrow therapeutic index of many anticancer agents, coupled with significant inter-patient variability in drug metabolism and clearance, underscores the critical need for TDM in oncology.
Despite its potential benefits, the adoption of TDM in routine oncology practice has been inconsistent. Challenges such as the lack of standardized protocols, limited availability of rapid and reliable assays, and the complexity of interpreting drug concentrations in the context of combination therapies have hindered its widespread use. Moreover, the emergence of targeted therapies and immunotherapies has introduced new complexities, as traditional TDM approaches may not be directly applicable.
This review aims to provide a comprehensive overview of the current state of TDM in anticancer drug therapy, highlighting the rationale, challenges, and future directions. We will explore the role of TDM in dose individualization, the integration of pharmacogenomics, and the potential of novel technologies such as real-time monitoring and microsampling. By synthesizing the latest evidence, we hope to offer insights that can guide clinical practice and research in this evolving field.
Loading authentic research manuscript (Pages 1–5)...
John Smith, Emily Johnson, Michael Brown, Sarah Davis (2026). Therapeutic Drug Monitoring of Anticancer Drugs: A Review of Current Practices and Future Directions. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-024-01234-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is therapeutic drug monitoring (TDM) in oncology?
TDM is the measurement of drug concentrations in blood or other biological fluids to guide dosing decisions. In oncology, it helps optimize the efficacy and safety of anticancer drugs by tailoring doses to individual patients.
Why is TDM important for anticancer drugs?
Anticancer drugs often have a narrow therapeutic index, meaning the difference between a toxic and a subtherapeutic dose is small. TDM helps maintain drug levels within the optimal range, improving outcomes and reducing adverse effects.
What are the challenges of implementing TDM in clinical practice?
Challenges include the lack of standardized protocols, limited availability of rapid assays, high costs, and the complexity of interpreting results in combination therapies. Additionally, the emergence of targeted therapies may require new TDM approaches.
How does pharmacogenomics enhance TDM?
Pharmacogenomics studies how genetic variations affect drug metabolism and response. By integrating genetic information, TDM can be further personalized, allowing for more precise dosing and prediction of toxicity.
What are the future directions of TDM in oncology?
Future directions include the development of real-time monitoring devices, microsampling techniques, and the integration of artificial intelligence to interpret complex data. These innovations aim to make TDM more accessible and effective.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.